Table 3.

Multiple Stepwise Logistic Regression Analysis of the Ratio of Serum Asprosin to Risk of Diabetic Nephropathy

	Tertile 1	Tertile 2	Tertile 3	P value for Trend
Model 1
Total	1	1.297 (0.836–2.012)	2.560 (1.592–4.116)	<0.001
Male	1	1.241 (0.557–2.765)	2.313 (1.275–4.195)	0.003
Female	1	2.331 (1.139–4.770)	4.871 (2.126–11.163)	<0.001
Model 2				<0.01
Total	1	1.100 (0.669–1.809)	2.010 (1.152–3.505)	0.002
Male	1	0.848 (0.338–2.125)	1.785 (0.884–3.604)	0.028
Female	1	2.189 (0.997–4.805)	3.748 (1.466–9.581)	0.001
Model 3				0.014
Total	1	1.055 (0.636–1.751)	1.823 (1.026–3.238)	0.043
Male	1	0.858 (0.341–2.163)	1.617 (0.789–3.314)	0.129
Female	1	2.348 (1.028–5.366)	3.725 (1.419–9.779)	0.007

Notes: Data are presented as odds ratio (95% confidence interval) compared with tertile 1. Participants without diabetic nephropathy (DN) were defined as 0 and those with DN as 1. Model 1, without adjusted variable; Model 2, with adjusted for duration of diabetes mellitus, systolic blood pressure, glycated hemoglobin, estimated glomerular filtration rate; Model 3, model 2 with additional adjustment for age, BMI, triglycerides and ACEI/ARB drug use; sersum asprosin tertile 1, <295.4 pg/mL for total, <282.0 pg/mL for male and <266.2 pg/mL for female; sersum asprosin tertile 2, 295.4–367.0 pg/mL for total, 282.0–315.6 pg/mL for male and 266.2–344.5 pg/mL for female; sersum asprosin tertile 3, >344.5 pg/mL for total, >315.6 pg/mL for male and >344.5 pg/mL for female.